Study of the effect of vitamin D supplementation on glycemic control in type 2 diabetic prevalent hemodialysis patients

• Published in: Hemodialysis international 2015-10, Vol.19 (S3), p.S11-S19
• Main Authors: Ibrahim, Mohamed A., Sarhan, Iman I., Halawa, Mohamed R., Afify, Essam N., Hebah, Hayam A., Al-Gohary, Eman A., El-Shazly, Islam O.
• Format: Article
• Language: English
• Subjects: Blood Glucose - analysis; Diabetes Mellitus, Type 2 - drug therapy; Dietary Supplements - analysis; Female; glucoparameters; hemodialysis; Humans; Male; Middle Aged; Renal Dialysis - methods; type 2 diabetes mellitus; Vitamin D; Vitamin D - administration & dosage; Vitamin D - analogs & derivatives; Vitamin D Deficiency - complications; Vitamin D Deficiency - drug therapy
• ISSN: 1492-7535; 1542-4758
• DOI: 10.1111/hdi.12347

Vitamin D is claimed to have an adjuvant effect on glycemic control by dual action on pancreatic β‐cells and insulin resistance. The aim of this study was to assess the possible effect of short‐term alfacalcidol supply on glycemic control in type 2 diabetic hemodialysis (HD) patients. Twenty type 2 diabetic HD patients (using diet and oral drugs but not insulin) were randomly selected from our dialysis unit as well as 20 non‐diabetic HD patients as control. A third group of 12 healthy subjects were studied as well. All three groups were similar in age, sex, and body mass index. Oral alfacalcidol therapy was administrated daily as recommended by Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for 12 weeks guided by monthly serum phosphorus and CaxPO4 product. Corrected total calcium, phosphorus, intact parathyroid hormone, 25‐hydroxy vitamin D (25[OH]D), and glucoparameters (fasting blood glucose, glycated hemoglobin [HbA1c%], insulin resistance by homeostatic model assessment, and β‐cell function by HOMA‐β%) were measured under basal conditions and after 3 months of therapy. 25(OH)D was non‐significantly lower in diabetic than non‐diabetic HD patients, but significantly lower than healthy subjects at the start of the study. However, vitamin D level increased significantly after 3 months of trial, although the levels did not reach normal values. This vitamin D rise was associated with highly significant improvement in concentrations of fasting blood sugar (FBS), fasting insulin, HbA1c%, and HOMA‐β‐cell function in diabetic and non‐diabetic controls. However, there was a significant rise in insulin resistance after treatment. The percentage of change was evident more in diabetics regarding FBS and 25(OH)D concentration. Adjustment of 25(OH)D level in type 2 diabetic prevalent HD patients may improve, at least with short‐term therapy, glycemic control mainly through improving β‐cell function.